Media headlines about Geron (NASDAQ:GERN) have trended very negative on Friday, InfoTrie Sentiment reports. The research group scores the sentiment of media coverage by reviewing more than 6,000 news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Geron earned a media sentiment score of -3.67 on their scale. InfoTrie also assigned media coverage about the biopharmaceutical company an news buzz score of 10 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company’s share price in the next several days.
These are some of the media headlines that may have impacted Geron’s score:
- Did Geron’s Big Announcement Just Go Unnoticed? – Yahoo Finance (finance.yahoo.com)
- Did Geron's Big Announcement Just Go Unnoticed? (finance.yahoo.com)
- Take a snapshot of Stock:: Geron Corporation, (NASDAQ: GERN) – NewsSmooth (newssmooth.com)
- Geron Corporation (GERN) Stock: A Biotech Stock That’s Headed Up – iWatch Markets (iwatchmarkets.com)
Several research analysts have recently issued reports on GERN shares. BidaskClub upgraded Geron from a “hold” rating to a “buy” rating in a research note on Saturday, March 16th. BTIG Research started coverage on Geron in a research note on Tuesday, February 12th. They issued a “buy” rating and a $4.00 price objective for the company. B. Riley upgraded Geron from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $1.50 to $3.25 in a research note on Thursday, January 31st. Finally, Needham & Company LLC upgraded Geron from a “hold” rating to a “buy” rating and set a $3.00 price objective for the company in a research note on Tuesday, April 9th. Three research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $3.01.
Geron (NASDAQ:GERN) last posted its earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.07) by $0.02. The firm had revenue of $0.06 million for the quarter, compared to analyst estimates of $0.23 million. Geron had a negative return on equity of 17.53% and a negative net margin of 3,713.04%. Research analysts expect that Geron will post -0.34 EPS for the current fiscal year.
In related news, EVP Melissa Kelly Behrs sold 120,635 shares of the firm’s stock in a transaction dated Tuesday, April 9th. The stock was sold at an average price of $2.00, for a total transaction of $241,270.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 8.20% of the stock is owned by company insiders.
Geron Company Profile
Geron Corporation, a clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for hematologic myeloid malignancies. The company supports the clinical stage development of imetelstat, a telomerase inhibitor for the treatment of hematologic myeloid malignancies.
See Also: Retained Earnings
Receive News & Ratings for Geron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Geron and related companies with MarketBeat.com's FREE daily email newsletter.